@article{e697b927b98047cd8daa719627e49c07,
title = "The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)",
author = "Sekeres, {Mikkael A.} and Swern, {Arlene S.} and Aristoteles Giagounidis and List, {Alan F.} and Dominik Selleslag and Moshe Mittelman and Brigitte Schlegelberger and Gudrun G{\"o}hring and Li, {Jack Shiansong} and Sugrue, {Mary M.} and Pierre Fenaux",
note = "Funding Information: Celgene Corporation provided funding for this study. The authors developed the concept for this study and reviewed primary statistical data to draw conclusions from analyses. The authors received editorial support provided by James O{\textquoteright}Reilly, PhD, from Excerpta Medica, funded by Celgene Corporation. The authors had full access to the data and are fully responsible for content and editorial decisions for this manuscript. Funding Information: Dr. Sekeres has received research funding from Celgene Corporation. Dr. Swern and Dr. Li are employees of and hold equity in Celgene Corporation. Dr. Giagounidis is a consultant for and has received honoraria from Celgene Corporation. Dr. List is a consultant for and has received honoraria and research funding from Celgene Corporation. Dr. Selleslag is a consultant for and has received honoraria and research funding from Celgene Corporation, Novartis, Amgen, and GSK. Dr. Mittelman is a consultant for and has received honoraria and research funding from Celgene Corporation. Dr. Schlegelberger and Dr. G{\"o}hring have no conflicts of interest to disclose. Dr. Sugrue is a former employee of and holds equity in Celgene Corporation. Dr. Fenaux has received honoraria and research funding from Celgene Corporation.",
year = "2018",
month = oct,
day = "1",
doi = "10.1038/s41408-018-0126-z",
language = "אנגלית",
volume = "8",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "10",
}
